Curis, Inc. (NASDAQ:CRIS) Files An 8-K Regulation FD DisclosureItem 7.01.
From time to time, we conduct meetings with third parties in which we utilize a corporate slide presentation. A copy of our current corporate slide presentation, dated September 2017, is attached as Exhibit 99.1 to this Current Report on Form 8-K and, among other things, provides for an update on our recently announced data related to CA-170. The attached presentation is incorporated herein by reference.
The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.
On September11, 2017, the Company issued a press release announcing its presentation of preliminary data from the dose escalation stage of the Phase 1 trial of CA-170 at the European Society for Medical Oncology 2017 Congress. As a result of the initial safety data and preliminary evidence of clinical benefit observed in the trial, the Company’s collaborator and discoverer of CA-170, Aurigene Discovery Technologies Limited, announced plans to initiate a Phase 2 trial of CA-170 to be conducted at sites in India.
The full text of the press release issued in connection with this announcement is attached as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference. There is one update to the information in the press release, such that in addition to the four immunotherapy treatment-naive patients treated with CA-170 who experienced tumor shrinkage, one patient who had experienced prior treatment also experienced tumor shrinkage.
| Item 7.01. | Financial Statements and Exhibits. |
(d) Exhibits.
CURIS INC ExhibitEX-99.1 2 d454564dex991.htm EX-99.1 EX-99.1 Corporate Presentation September 2017 Exhibit 99.1 © Curis,…To view the full exhibit click here
About Curis, Inc. (NASDAQ:CRIS)
Curis, Inc. is a biotechnology company. The Company is engaged in the development and commercialization of drug candidates for the treatment of human cancers. The Company’s drug candidate, CUDC-907, is an orally available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. Its product pipeline includes CA-170, which is an oral small molecule drug candidate; CA-4948, which is an oral small molecule drug candidate that is designed to inhibit the interleukin-1 receptor-associated kinase 4 (IRAK4) kinase; Erivedge, which is an orally bioavailable small molecule, and is designed to selectively inhibit the Hedgehog signaling pathway; CUDC-427, which is an oral, small molecule Smac mimetic that is designed to promote cancer cell death by antagonizing inhibitor of apoptosis (IAP) proteins, and CUDC-305, which is an oral HSP90 inhibitor for the development in advanced lung cancer.
